UPLIFT Trial: Abemaciclib Safely Boosts PSMA for Better Radioligand Therapy in Advanced Prostate Cancer

/in , , , /by

The UPLIFT trial is a phase 1/2 study testing a new combo for metastatic castrate-resistant prostate cancer. Researchers at the University of California, San Francisco, designed this trial to boost the power of 177Lu-PSMA-617, a targeted radiation drug called a radioligand therapy. That drug latches onto PSMA, a protein stamped all over prostate cancer cells, […]

Read more

Early Results From a Phase 1 Trial for MRT-2359 Plus Enzalutamide in mCRPC

/in , , , /by

MRT-2359 is a daily pill that destroys certain cancer-driving proteins, including the androgen receptor (AR), MYC, and Cyclin D1, by blocking a key step in how cells read genetic instructions. This approach targets metastatic castration-resistant prostate cancer (mCRPC), where AR mutations in the ligand-binding domain (LBD) allow tumors to grow despite hormone-blocking drugs like enzalutamide. […]

Read more

Phase 1 PAnTHa Trial: mCRPC First Data

/in , , /by

²²⁵Ac‑PSMA‑Trillium (BAY3563254) is an experimental treatment that delivers targeted alpha radiation to prostate cancer cells. It combines a highly selective PSMA‑binding molecule with an albumin‑binding domain that helps it stay in the bloodstream longer and reach tumors more effectively. The radioactive component, actinium‑225, is attached using a stable Macropa chelator to increase safety and stability. […]

Read more

BRCAAway OS Update: Abiraterone + Olaparib Extends Survival by 5 Years in HRRm mCRPC

/in , , /by

The BRCAAway trial brings strong new data on treating metastatic castration-resistant prostate cancer, or mCRPC, in patients with specific DNA repair defects known as homologous recombination repair mutations, or HRRm. This phase 2 study tested abiraterone alone, olaparib alone, or the two drugs together as first-line therapy. It focused on patients with germline or somatic […]

Read more

pre|CISION Platform Update: AVA6103 Outperforms Leading ADC, Phase 1 Dosing Imminent

/in , /by

Since October 2025, when the pre|CISION platform first demonstrated its potential to deliver dual payloads like MMAE and exatecan from a single molecule in prostate cancer models, significant new data has emerged that strengthens its case as a next-generation targeted therapy. The platform’s ability to exploit fibroblast activation protein (FAP) in the tumor microenvironment for […]

Read more

UPDATE: SECuRE Trial, Another Complete Responder

/in , , /by

A striking new update from the ongoing SECuRE trial has revealed yet another participant achieving undetectable PSA levels alongside a completely negative PSMA PET scan, underscoring the potential of 67Cu-SAR-bisPSMA in advanced prostate cancer treatment. This 76-year-old patient, facing progressive metastatic castration-resistant prostate cancer (mCRPC) 15 years after initial diagnosis, started with a baseline PSA […]

Read more

Evolutionary Oncology: A New Research Validates This Approach in Preclinical Models

/in , /by

Researchers at Trinity College Dublin and Moffitt Cancer Center have uncovered a promising prostate cancer breakthrough: radiation-resistant tumor cells become unexpectedly vulnerable to attack by natural killer (NK) immune cells, presenting a strategic “evolutionary double-bind” that could transform treatment approaches. This discovery challenges traditional views of therapy resistance, showing that when prostate cancer cells adapt […]

Read more

UPDATE: VIR-5500 Results From Phase 1 Trial Look Very Promising

/in , , /by

Recent clinical data from a Phase 1 dose-escalation trial highlight VIR-5500 as a highly promising therapeutic candidate for patients with heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is a dual-masked, bispecific T-cell engager designed to selectively target the prostate-specific membrane antigen (PSMA) while minimizing systemic toxicity. The therapy employs a specialized PRO-XTEN masking technology […]

Read more